Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies
| Errataetall: |
CommentOn: J Clin Pharmacol. 2016 Feb;56(2):143-51. - PMID 26044116 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - 56(2016), 2 vom: 05. Feb., Seite 152-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Greenblatt, David J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 24.08.2016 Date Revised 02.12.2018 published: Print-Electronic CommentOn: J Clin Pharmacol. 2016 Feb;56(2):143-51. - PMID 26044116 Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcph.609 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM25150610X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM25150610X | ||
| 003 | DE-627 | ||
| 005 | 20231224162147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.609 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0838.xml |
| 035 | |a (DE-627)NLM25150610X | ||
| 035 | |a (NLM)26239522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Greenblatt, David J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Clin Pharmacol. 2016 Feb;56(2):143-51. - PMID 26044116 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Cytochrome P-450 CYP3A Inhibitors |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g 56(2016), 2 vom: 05. Feb., Seite 152-6 |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2016 |g number:2 |g day:05 |g month:02 |g pages:152-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.609 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2016 |e 2 |b 05 |c 02 |h 152-6 | ||